

# FASKEN

Fasken Martineau DuMoulin LLP  
Barristers and Solicitors  
Patent and Trade-mark Agents

333 Bay Street, Suite 2400  
P.O. Box 20  
Toronto, Ontario M5H 2T6  
Canada

T +1 416 366 8381  
+1 800 268 8424  
F +1 416 364 7813  
fasken.com

June 11, 2020  
File No.: 264476.00040

British Columbia Securities Commission  
Alberta Securities Commission  
The Manitoba Securities Commission  
Ontario Securities Commission

Dear Sirs/Mesdames:

**Re: Algernon Pharmaceuticals Inc. (the “Issuer”)  
Final Short Form Prospectus**

We refer to the final short form prospectus dated June 11, 2020 of the Issuer in relation to the offering of units consisting of one class A common share and one class A common share purchase warrant issuable on the conversion of special warrants of the Issuer (the “**Prospectus**”).

We hereby consent to the reference to our firm name in the introduction section of the Prospectus and under the heading “Legal Matters” and to the reference to our firm name and to the use of our opinion under the heading “Eligibility for Investment” in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that is derived from our opinions referred to above or that is within our knowledge as a result of the services we performed in connection with such opinions.

This letter is delivered to the addressees pursuant to the requirements of Section 4.2(a)(vii) of National Instrument 44-101.

Yours truly,

***“FASKEN MARTINEAU DuMOULIN LLP”***

